

SEQUENCE LISTING

<110> Stangl, Verena  
Stangl, Karl  
Lorenz, Mario

<120> Use of a Proteosome Inhibitor in the Treatment of Endothelial  
Dysfunction and/or in a Low-Dose Proteosome Inhibitor Therapy

<130> 2958-128

<140> 10/522,706  
<141> 2005-01-28

<150> PCT/EP03/08495  
<151> 2003-07-31

<150> EP 02 017 234.2  
<151> 2002-07-31

<160> 17

<170> PatentIn version 3.3

<210> 1  
<211> 4  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic proteosome inhibitor with binding affinity for human  
proteins involved in eNOS regulation

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> modified with carbobenzoxy group

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> modified with OBut or OtBu group

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> modified with H or CHO

<400> 1

Ile Gly Ala Leu  
1

<210> 2  
<211> 4  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic proteasome inhibitor with binding affinity for human proteins involved in eNOS regulation

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> modified with vinylsulfone group

<400> 2

Tyr Leu Leu Leu  
1

<210> 3  
<211> 4  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic proteasome inhibitor with binding affinity for human proteins involved in eNOS regulation

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> modified with adamantaneacetyl group

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> modified with 3 (6-aminohexanoyl) groups

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> modified with vinylsulfone group

<400> 3

Tyr Leu Leu Leu  
1

<210> 4  
<211> 4  
<212> PRT

<213> Artificial  
 <220>  
 <223> synthetic proteasome inhibitor with binding affinity for human proteins involved in eNOS regulation  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> modified with adamantaneacetyl group  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> biotinylated  
 <220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> modified with 3 (6-aminohexanoyl) groups  
 <220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> modified with vinylsulfone group  
 <400> 4  
 Lys Leu Leu Leu  
 1  
 <210> 5  
 <211> 4  
 <212> PRT  
 <213> Artificial  
 <220>  
 <223> synthetic proteasome inhibitor with binding affinity for human proteins involved in eNOS regulation  
 <220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> modified with acetylmethyl group  
 <220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> modified with epoxomicin  
 <400> 5

Ile Ile Thr Leu  
1

<210> 6  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 6  
ggcatcacca ggaagaagac c

21

<210> 7  
<211> 19  
<212> DNA  
<213> Homo sapiens

<400> 7  
ttcactcgct tcgccatca

19

<210> 8  
<211> 29  
<212> DNA  
<213> Homo sapiens

<400> 8  
taaagaagtg gccaacgccg tgaagatct

29

<210> 9  
<211> 25  
<212> DNA  
<213> Homo sapiens

<400> 9  
agtctggctt atatccaaca cttcg

25

<210> 10  
<211> 22  
<212> DNA  
<213> Homo sapiens

<400> 10  
gacttttgctt tccttggtca gg

22

<210> 11  
<211> 26  
<212> DNA  
<213> Homo sapiens

<400> 11

tttcaccagc aagcttgcca ccttga	26
<210> 12	
<211> 28	
<212> DNA	
<213> Bos taurus	
<400> 12	
tttaccataa gagactggac cagaagtt	28
<210> 13	
<211> 22	
<212> DNA	
<213> Bos taurus	
<400> 13	
attgacagca ctggcttagg ca	22
<210> 14	
<211> 25	
<212> DNA	
<213> Bos taurus	
<400> 14	
gctataagtt ctttgccgac ctggt	25
<210> 15	
<211> 26	
<212> DNA	
<213> Bos taurus	
<400> 15	
ttctgttcag tgctttgatg taatcc	26
<210> 16	
<211> 22	
<212> DNA	
<213> Bos taurus	
<400> 16	
agtagctggt tccctccgaa gt	22
<210> 17	
<211> 19	
<212> DNA	
<213> Bos taurus	
<400> 17	
ttgcgagagc gccagctat	19